Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

Recruiting Observational Study
Primary Ovarian Leiomyosarcoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Female
Study type
Observational
Participants needed
30 (estimated)
Sponsor
Azienda USL Reggio Emilia - IRCCS · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through c…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of primary leiomyosarcoma of the ovary; * Patients diagnosed with POLMS for whom data relating to diagnosis and treatment are available. * Aged between 18 and 99 years Exclusion Criteria: \- All patients with other forms of ovarian sarcoma (rhabdomyosarcomas, fibro…
Contacts

Vincenzo Dario Mandato, MD

+39 0522 295467

vincenzodario.mandato@ausl.re.it

CONTACT